Company News

2026-08-21

Strengthening Global R&D | Dr. David Nicholson and Dr. Stephen Fawell Join Haixi Pharmaceuticals’ Scientific Advisory Board

Fujian Haixi Pharmaceuticals Co., Ltd. (HKEX: 2637) is pleased to announce that Dr. David Nicholson and Dr. Stephen Fawell have joined the Company’s Scientific Advisory Board (SAB), further strengthening Haixi Pharmaceuticals’

More

2026-08-18

HX9428 for the Treatment of Neovascular Age-Related Macular Degeneration Granted Fast Track Designation (FTD) by U.S. FDA

The board of directors of the Company is pleased to announce that HX9428, the candidate molecule of the innovative drug project HXP056 independently developed by the Company, was granted Fast Track Designation (“FTD”) by the U.S.

More

2026-08-05

Haixi Pharma HX9428 Achieves New Breakthrough | U.S. FDA IND Approved, Parallel Phase II Clinical Trials Progress in China and the U.S.

the candidate molecule of HXP056, which was discovered and developed by the Company for the treatment of neovascular age-related macular degeneration ( nAMD), has been approved by the U.S. Food and Drug Administration (the “FDA”).

More

2026-07-14

HXP089 Investigational New Drug (IND) Application for the Treatment of Glioblastoma Approved by National Medical Products Administration (NMPA)

More

2026-08-21

Expanded Access Policy for HX9428

Fujian Haixi Pharmaceuticals Co., Ltd. is committed to the discovery and development of innovative medicines that address significant unmet medical needs and have the potential to improve treatment outcomes and quality of life for patients.

More

2026-07-10

Launch of Phase III Osteosarcoma Clinical Trial for C019199 Tablets by Haixi Pharmaceuticals

本公司董事會（「董事會」）欣然宣佈，本公司自主研發的C019199片正式啓動針對既往至少二線治療失敗的骨肉瘤的III期臨床試驗(CTR20261818)，相關信息已獲中國國家藥品監督管理局(NMPA)藥品審評中心(CDE)藥物臨床試驗登記與資訊公示平台公示。

More